{"product_id":"es20054","title":"RUNX1 (Acetyl Lys24) rabbit pAb","description":"\u003cstrong\u003eApplications:\u003c\/strong\u003e WB; ELISA\u003cbr\u003e\u003cstrong\u003eReactivity:\u003c\/strong\u003e Human;Mouse;Rat\u003cbr\u003e\u003cstrong\u003eSource:\u003c\/strong\u003e Rabbit\u003cbr\u003e\u003cstrong\u003eDilution:\u003c\/strong\u003e WB 1:1000-2000 ELISA 1:5000-20000\u003cbr\u003e\u003cstrong\u003eImmunogen:\u003c\/strong\u003e Synthesized peptide derived from human RUNX1 (Acetyl Lys24)\u003cbr\u003e\u003cstrong\u003eStorage_stability:\u003c\/strong\u003e -20°C\/1 year\u003cbr\u003e\u003cstrong\u003eClonality:\u003c\/strong\u003e Polyclonal\u003cbr\u003e\u003cstrong\u003eIsotype:\u003c\/strong\u003e IgG\u003cbr\u003e\u003cstrong\u003eConcentration:\u003c\/strong\u003e 1 mg\/ml\u003cbr\u003e\u003cstrong\u003eObserved_band(KD):\u003c\/strong\u003e 50kD\u003cbr\u003e\u003cstrong\u003eHuman_gene_id:\u003c\/strong\u003e 861\u003cbr\u003e\u003cstrong\u003eHuman_swiss_prot_no:\u003c\/strong\u003e Q01196\u003cbr\u003e\u003cstrong\u003eSubcellular_location:\u003c\/strong\u003e Nucleus.\u003cbr\u003e\u003cstrong\u003eOther_name:\u003c\/strong\u003e Runt-related transcription factor 1 (Acute myeloid leukemia 1 protein;Core-binding factor subunit alpha-2;CBF-alpha-2;Oncogene AML-1;Polyomavirus enhancer-binding protein 2 alpha B subunit;PEA2-alpha B;PEBP2-alpha B;SL3-3 enhancer factor 1 alpha B subunit;SL3\/AKV core-binding factor alpha B subunit)\u003cbr\u003e\u003cstrong\u003eBackground:\u003c\/strong\u003e alternative products:Additional isoforms seem to exist,caution:The fusion of AML1 with EAP in T-MDS induces a change of reading frame in the latter resulting in 17 AA unrelated to those of EAP.,disease:A chromosomal aberration involving RUNX1\/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP, MSD1 or EVI1.,disease:A chromosomal aberration involving RUNX1\/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.,disease:A chromosomal aberration involving RUNX1\/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1\/MTG8\/ETO.,disease:A chromosomal aberration involving RUNX1\/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP, MSD1 or EVI1.,disease:A chromosomal aberration involving RUNX1\/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.,disease:A chromosomal aberration involving RUNX1\/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.,disease:Defects in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]. FPDMM is an autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.,domain:A proline\/serine\/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes.,function:CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation.,PTM:Methylated.,PTM:Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with MYST3.,similarity:Contains 1 Runt domain.,subunit:Heterodimer with CBFB. RUNX1 binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Isoform AML-1L can neither bind DNA nor heterodimerize. Interacts with TLE1 and THOC4. Interacts with ELF1, ELF2 and SPI1. Interacts via its Runt domain with the ELF4 N-terminal region. Interaction with ELF2 isoform 2 (NERF-1a) may act to repress RUNX1-mediated transactivation. Interacts with MYST3 and MYST4. Interacts with SUV39H1, leading to abrogate the transactivating and DNA-binding properties of RUNX1.,tissue specificity:Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.,","brand":"ELK Biotechnology","offers":[{"title":"50μL","offer_id":50413659357464,"sku":"ES20054","price":250.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/danabiosci.com\/products\/es20054","provider":"Dana Bioscience","version":"1.0","type":"link"}